Phase-separating fusion proteins drive cancer by upsetting transcription regulation
Open Access
- 2 October 2025
- journal article
- research article
- Published by Springer Nature in Genome Biology
- Vol. 26 (1) , 1-35
Abstract
Numerous cellular processes rely on biomolecular condensates formed through liquid–liquid phase separation (LLPS). Recently, it has become evident that somatic mutations can interfere with or over-activate the formation of phase-separated condensates. Here, we set out to systematically study the connection between cancer and biological condensation, specifically mapping the extent to which LLPS is affected in cancer and understanding the molecular pathomechanisms and therapeutic consequences of mutations affecting LLPS scaffolds. We identify both known and novel combinations of molecular functions that are specific to oncogenic fusion proteins and thus have a high potential for driving tumorigenesis. Protein regions driving condensate formation show an increased association with DNA- or chromatin-binding domains of transcription regulators within oncogenic fusion proteins, indicating a common molecular mechanism underlying several soft tissue sarcomas and hematologic malignancies where phase-separation-prone oncogenic fusion proteins form abnormal condensates along the DNA and thereby dysregulate gene expression programs. We find that proteins initiating LLPS are frequently implicated in somatic cancers, even surpassing their involvement in neurodegeneration. Our data shows that cancer-driving LLPS scaffolds tend to be potent oncogenes, giving rise to dominant phenotypes and lacking targeting options by current FDA-approved drugs. Finding the currently missing drugs to shut down oncogenic fusion proteins, to disrupt the condensation enabled by them, and to offset their downstream effects could provide cancer drugs widely applicable to diverse cancer incidences previously defying standard treatments.Keywords
All Related Versions
Funding Information
- Fonds Wetenschappelijk Onderzoek (FWOTM1124)
- Agentschap Innoveren en Ondernemen (HBC.2022.0194)
- Nemzeti Kutatási, Fejlesztési és Innovaciós Alap (K-124670, FK-142285)
- Horizon 2020 Framework Programme (952334)
- Nemzeti Kutatási Fejlesztési és Innovációs Hivatal (RGH 151464)
- Magyar Tudományos Akadémia (BO/00174/22)
This publication has 149 references indexed in Scilit:
- A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5Blood, 2006
- NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemiaBlood, 2005
- Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemiaNature Reviews Cancer, 2005
- Regulation of the c-Abl and Bcr–Abl tyrosine kinasesNature Reviews Molecular Cell Biology, 2004
- High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARα expressionBlood, 2003
- Impairment of MAD2B–PRCC interaction in mitotic checkpoint defective t(X;1)-positive renal cell carcinomasProceedings of the National Academy of Sciences, 2001
- NUP98–HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in miceThe EMBO Journal, 2001
- Gene Ontology: tool for the unification of biologyNature Genetics, 2000
- CREB Binding Protein Interacts with Nucleoporin-Specific FG Repeats That Activate Transcription and Mediate NUP98-HOXA9 OncogenicityMolecular and Cellular Biology, 1999
- PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR.The EMBO Journal, 1993